QIAGEN, ID Solutions partner to boost dPCR in oncology

NETHERLANDS – QIAGEN has announced a strategic partnership and co-marketing agreement with French biotech firm ID Solutions to boost the global availability of digital PCR (dPCR) assays for oncology research.

This collaboration combines QIAGEN’s global reach and expertise in laboratory automation with ID Solutions’ strength in assay development and manufacturing.

Under the new agreement, ID Solutions will produce dPCR assays designed for use on QIAGEN’s QIAcuity platforms.

These assays are tailored for non-clinical research and can detect multiple mutations at once in cell-free DNA (cfDNA) from blood plasma and genomic DNA (gDNA) from FFPE tissue samples.

QIAGEN plans to launch these products first in Europe, with the possibility of expanding to other regions in the future.

The deal supports QIAGEN’s goal of accelerating adoption of the QIAcuity digital PCR system in cancer research.

It also broadens QIAGEN’s assay portfolio, complementing its existing PanCancer Kits and more than 200 LNA Mutation Assays available through its GeneGlobe platform.

GeneGlobe connects researchers with a large database of over 10,000 biological targets, including genes, miRNAs, and disease pathways.

According to Simona Grandits, Vice President and Head of Commercial Operations for QIAGEN in EMEA, this partnership underlines the company’s commitment to delivering complete dPCR solutions.

She noted that the new assays will help researchers generate faster and more consistent results on the QIAcuity system.

ID Solutions CEO Lise Grewis added that the collaboration aligns with their mission to expand access to high-quality, research-use-only assays on advanced platforms.

By partnering with QIAGEN, ID Solutions can help bring their dPCR innovations to more labs worldwide.